MedTrace Logo

Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events

NCT00317005 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2018-07-26

No results posted yet for this study

Summary

Homocysteine recently gained access to the category of risk factor for the development of atherosclerotic cardiovascular disease in the general population. Chronic renal failure patients, even before being introduced to dialysis therapy have almost universal elevation of serum homocysteine; when on dialysis their mortality is above 50% related to cardiovascular disease that we might now speculate, with a contribution of potentially toxic levels of the aminoacid homocysteine.

Conditions

Interventions

DRUG

folate treatment

Sponsors & Collaborators

  • Universidade Estadual de Londrina

    lead OTHER

Principal Investigators

  • Altair J Mocelin, MD PHD · Nephrology, University Hospital, State University of Londrina

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Completion
2005-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317005 on ClinicalTrials.gov